Mereo Biopharma Group PLC Form 4 insider transactions

Charles Sermon, General Counsel of Mereo BioPharma Group plc, acquired 65,600 American Depositary Shares (ADS) representing ordinary shares due to the vesting of performance-based restricted stock units.

Christine Ann Fox, CFO of Mereo BioPharma Group plc, acquired 60,000 American Depositary Shares (ADS) after performance-based restricted stock units vested on September 11, 2024.

Chief Scientific Officer John A. Lewicki acquired 46,000 American Depositary Shares (ADS) of Mereo BioPharma Group plc following the vesting of performance-based restricted stock units.

CEO Denise Scots-Knight acquired 188,060 American Depositary Shares (ADS) of Mereo BioPharma Group plc on September 11, 2024, following the vesting of performance-based restricted stock units.

Alexandra Hughes-Wilson, a Mereo BioPharma Group plc officer, reports the acquisition and disposal of American Depositary Shares (ADS) through option exercises and vesting of restricted stock units.

Director Deepika Pakianathan reports the acquisition and disposal of Mereo BioPharma Group plc American Depositary Shares (ADS) and the exercise of share options on August 22, 2024.

Charles Sermon, General Counsel of Mereo BioPharma Group plc, sold American Depositary Shares (ADS) to cover tax withholding obligations related to vested restricted stock units.

John A. Lewicki, Chief Scientific Officer of Mereo BioPharma Group plc, sold shares to cover tax withholding obligations related to vested restricted stock units.

Christine Fox, CFO of Mereo BioPharma Group plc, sold American Depositary Shares (ADS) to cover tax withholding obligations related to vested performance-based restricted stock units.

Mereo BioPharma Group plc CEO, Denise Scots-Knight, sold American Depositary Shares (ADSs) to cover tax withholding obligations related to vested performance-based restricted stock units.

Alexandra Hughes-Wilson, a Mereo BioPharma Group plc officer, sold American Depositary Shares (ADS) to cover tax withholding obligations related to vested restricted stock units.

Chief Scientific Officer John A. Lewicki acquired 69,000 American Depositary Shares (ADS) of Mereo BioPharma Group plc due to the vesting of performance-based restricted stock units.

CEO Denise Scots-Knight acquired 282,090 American Depositary Shares (ADS) of Mereo BioPharma Group plc following the vesting of performance-based restricted stock units.

Charles Sermon, General Counsel of Mereo BioPharma Group plc, reports the acquisition of 98,400 American Depositary Shares (ADS) representing ordinary shares, due to the vesting of performance-based restricted stock units.

Christine Fox, CFO of Mereo BioPharma Group plc, reports the acquisition and disposal of shares related to performance-based restricted stock units (PSUs) that vested on June 21, 2024.

Alexandra Hughes-Wilson, a Mereo BioPharma Group plc officer, acquired 60,000 American Depositary Shares (ADS) after performance-based restricted stock units (PSUs) vested on June 21, 2024.

Rubric Capital Management LP reports acquisition of 1,754,350 American Depositary Shares of Mereo BioPharma Group plc at $3.99 per share, increasing its holdings to 15,307,347 ordinary shares.

Director Michael Wyzga reports the acquisition of 25,050 American Depositary Shares of Mereo BioPharma Group plc at a price of $3.99 per share.

Director Jeremy Bender reports the acquisition of 12,550 American Depositary Shares of Mereo BioPharma Group plc at a price of $3.99 per share.

Alexandra Hughes-Wilson, a Mereo BioPharma executive, amended a previous SEC filing to reflect that a reported transaction involving American Depositary Shares (ADS) was canceled before settlement.

Alexandra Hughes-Wilson, a Mereo BioPharma Group officer, sold shares to cover tax obligations, according to a recent SEC filing.